13. Literatur
-
1
Johnson D D, Palumbo P J, Chu C P.
Diabetic ketoacidosis in a community-based population.
Mayo Clin Proc.
1980;
55
83-88
EK III
-
2
Martin S, Kolb H.
Pathogenese und Immuntherapie des Diabetes mellitus Typ 1.
Diabet Stoffw.
1998;
7
17-24
EK IV
-
3
Bottazzo G F, Florin-Christensen A, Doniach D.
Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.
Lancet.
1974;
2
1279-1283
EK III
-
4
Palmer J P, Asplin C M, Clemons P et al.
Insulin antibodies in insulin-dependent diabetics before insulin treatment.
Science.
1983;
222
1337-1339
EK III
-
5
Wiest-Ladenburger U, Hartmann R, Hartmann U et al.
Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test.
Diabetes.
1997;
46
565-571
EK III
-
6
Bingley P J, Bonifacio E, Mueller P W.
Diabetes Antibody Standardization Program: first assay proficiency evaluation.
Diabetes.
2003;
52
1128-1136
EK III
-
7
Törn C, Mueller P W, Schlosser M et al.
Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2.
Diabetologia.
2008;
51
846-852
EK III
-
8
Schlosser M, Mueller P W, Torn C et al.
Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.
Diabetologia.
2010;
53
2611-2620
EK III
-
9
Imagawa A, Hanafusa T, Miyagawa J et al.
A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group.
N Engl J Med.
2000;
342
301-307
EK III
-
10 Scherbaum W A, Kiess W (eds). Deutsche Diabetes-Gesellschaft (DDG). Definition, Klassifikation und Diagnostik des Diabetes mellitus. http://http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Klassifikation_Update_2004.pdf EK IV
-
11
American Diabetes Association (ADA) .
American Diabetes Association: clinical practice recommendations 1997.
Diabetes Care.
1997;
20
S1-S70
EK IV
-
12
Alberti K G, Zimmet P Z.
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabet Med.
1998;
15
539-553
EK IV
-
13
DCCT Research Group .
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.
N Engl J Med.
1993;
329
977-986
EK I b
-
14
Wang P H, Lau J, Chalmers T C.
Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.
Lancet.
1993;
341
1306-1309
EK I b
-
15
DCCT Research Group .
Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.
Ophthalmology.
1995;
102
647-661
EK I b
-
16
Fanelli C G, Epifano L, Rambotti A M et al.
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM.
Diabetes.
1993;
42
1683-1689
EK II b
-
17
Fritsche A, Stefan N, Haring H et al.
Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes.
Ann Intern Med.
2001;
134
729-736
EK II b
-
18
Lachin J M, Genuth S, Nathan D M et al.
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial – revisited.
Diabetes.
2008;
57
995-1001
EK III
-
19
White N H, Sun W, Cleary P A et al.
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.
Arch Ophthalmol.
2008;
126
1707-1715
EK III
-
20
Nathan D M, Cleary P A, Backlund J Y et al.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
N Engl J Med.
2005;
353
2643-2653
EK II b
-
21
de Boer I, Kestenbaum B, Rue T C et al.
Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus.
Arch Intern Med.
2008;
168
1867-1873
EK I b und EK II a
-
22
Cleary P A, Orchard T J, Genuth S et al.
The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT / EDIC) Study.
Diabetes.
2006;
55
3556-3565
EK III
-
23
Retnakaran R, Hochman J, DeVries J H et al.
Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.
Diabetes Care.
2004;
27
2590-2596
EK I a
-
24
Fatourechi M M, Kudva Y C, Murad M H et al.
Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections.
J Clin Endocrinol Metab.
2009;
94
729-740
EK I a
-
25
Jeitler K, Horvath K, Berghold A et al.
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.
Diabetologia.
2008;
51
941-951
EK I a
-
26
Pickup J C, Sutton A J.
Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
Diabet Med.
2008;
25
765-774
EK II b
-
27
Bolli G B, Kerr D, Thomas R et al.
Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
Diabetes Care.
2009;
32
1170-1176
EK I b
-
28
Mukhopadhyay A, Farrell T, Fraser R B et al.
Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials.
Am J Obstet Gynecol.
2007;
197
447-456
EK I a
-
29 Farrar D, Tuffnell D J, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. CD005542 2007 EK I a
-
30
Chen R, Ben-Haroush A, Weismann-Brenner A et al.
Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions.
Am J Obstet Gynecol.
2007;
197
404-405
EK II b
-
31
Cypryk K, Kosinski M, Kaminska P et al.
Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections.
Pol Arch Med Wewn.
2008;
118
339-344
EK II b
-
32
Gimenez M, Conget I, Nicolau J et al.
Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study.
Acta Diabetol.
2007;
44
34-37
EK III
-
33 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) .Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-02. Version 1.0. http://http://www.iqwig.de/download/A05–02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf 2007 EK I a
-
34 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) .Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-01. Version 1.0. http://http://www.iqwig.de/download/A05–01_Abschlussbericht_Langwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf 2010 EK I a
-
35
Singh S R, Ahmad F, Lal A et al.
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.
CMAJ.
2009;
180
385-397
EK I a
-
36
Monami M, Marchionni N, Mannucci E.
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
Diabetes Obes Metab.
2009;
11
372-378
EK I a
-
37
Mullins P, Sharplin P, Yki-Jarvinen H et al.
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Clin Ther.
2007;
29
1607-1619
EK I a
-
38
Ashwell S G, Bradley C, Stephens J W et al.
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes.
Diabetes Care.
2008;
31
1112-1117
EK I b
-
39
Hermansen K, Fontaine P, Kukolja K K et al.
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Diabetologia.
2004;
47
622-629
EK I b
-
40
Brunner G A, Hirschberger S, Sendlhofer G et al.
Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus.
Diabet Med.
2000;
17
371-375
EK I b
-
41
Rave K, Klein O, Frick A D et al.
Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Diabetes Care.
2006;
29
1812-1817
EK I b
-
42
Scheen A J, Letiexhe M R, Lefebvre P J.
Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme.
Diabetes Metab.
1999;
25
157-162
EK II b
-
43
DeWitt D E, Hirsch I B.
Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.
JAMA.
2003;
289
2254-2264
EK I b
-
44
Hauner H, Stockamp B, Haastert B.
Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors.
Exp Clin Endocrinol Diabetes.
1996;
104
106-110
EK III
-
45
Vardar B, Kizilci S.
Incidence of lipohypertrophy in diabetic patients and a study of influencing factors.
Diabetes Res Clin Pract.
2007;
77
231-236
EK III
-
46
Johansson U B, Amsberg S, Hannerz L et al.
Impaired absorption of insulin aspart from lipohypertrophic injection sites.
Diabetes Care.
2005;
28
2025-2027
EK I b
-
47
Richardson T, Weiss M, Thomas P et al.
Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes.
Diabetes Care.
2005;
28
1801-1802
EK II a
-
48
Toeller M.
Evidenz-basierte Ernährungsempfehlungen zur Behandlung und Prävention des Diabetes mellitus.
Diabet Stoffw.
2005;
14
75-94
EK IV
-
49
Herpertz S, Petrak F, Albus C et al.
Evidenzbasierte Diabetes-Leitlinie DDG: Psychosoziale Interventionen bei Patienten mit Diabetes mellitus.
Diabet Stoffw.
2003;
12
35-58
EK IV
-
50
Hermanns N, Kulzer B, Krichbaum M.
Problemspezifische Patientenschulung. Übersicht zu einem wesentlichen Bestandteil der Diabetestherapie.
Diabetologe.
2008;
4
361-367
EK III
-
51
Hermanns N, Kulzer B.
Diabetesschulung – ein kritischer Überblick.
Diabetologe.
2008;
4
209-226
EK III
-
52
Mühlhauser I, Bruckner I, Berger M et al.
Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Dusseldorf Study.
Diabetologia.
1987;
30
681-690
EK II a
-
53
Sämann A, Mühlhauser I, Bender R et al.
Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study.
Diabetologia.
2005;
48
1965-1970
EK II b
-
54
Bott S, Bott U, Berger M et al.
Intensified insulin therapy and the risk of severe hypoglycaemia.
Diabetologia.
1997;
40
926-932
EK II b
-
55
DAFNE Study Group .
Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial.
BMJ.
2002;
325
746
EK I b
-
56
Cox D, Gonder-Frederick L, Polonsky W et al.
A multicenter evaluation of blood glucose awareness training-II.
Diabetes Care.
1995;
18
523-528
EK II b
-
57
Cox D J, Gonder-Frederick L, Julian D M et al.
Long-term follow-up evaluation of blood glucose awareness training.
Diabetes Care.
1994;
17
1-5
EK II b
-
58
Cox D J, Gonder-Frederick L, Polonsky W et al.
Blood glucose awareness training (BGAT-2): long-term benefits.
Diabetes Care.
2001;
24
637-642
EK II b
-
59
Broers S, le Cessie S, van Vliet K P et al.
Blood Glucose Awareness Training in Dutch Type 1 diabetes patients. Short-term evaluation of individual and group training.
Diabet Med.
2002;
19
157-161
EK II b
-
60
Kinsley B T, Weinger K, Bajaj M et al.
Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes.
Diabetes Care.
1999;
22
1022-1028
EK I b
-
61
Schachinger H, Hegar K, Hermanns N et al.
Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany.
J Behav Med.
2005;
28
587-594
EK I b
-
62
Kulzer B, Albus C, Herpertz S et al.
Psychosoziales und Diabetes mellitus.
Diabet Stoffw.
2010;
5
S139-S145
EK IV
-
63 Scherbaum W A, Haak T (eds). Deutsche Diabetes-Gesellschaft (DDG). Diabetes und Schwangerschaft. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. http://http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Schwangerschaft_2008.pdf 2008 EK IV
-
64 Scherbaum W A, Haak T (eds). Deutsche Diabetes-Gesellschaft (DDG). Körperliche Aktivität und Diabetes mellitus. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. http://http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Bewegung_2008.pdf 2008 EK IV
-
65
American Diabetes Association (ADA) .
Standards of medical care in diabetes – 2010.
Diabetes Care.
2010;
33
S11-S61
EK IV
-
66
Goldberg P A, Siegel M D, Sherwin R S et al.
Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.
Diabetes Care.
2004;
27
461-467
EK II b
-
67
Studer C, Sankou W, Penfornis A et al.
Efficacy and safety of an insulin infusion protocol during and after cardiac surgery.
Diabetes Metab.
2010;
36
71-78
EK II b
-
68
Golden S H, Peart-Vigilance C, Kao W H et al.
Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes.
Diabetes Care.
1999;
22
1408-1414
EK III
-
69
Husband D J, Thai A C, Alberti K G.
Management of diabetes during surgery with glucose-insulin-potassium infusion.
Diabet Med.
1986;
3
69-74
EK II b
-
70
Christiansen C L, Schurizek B A, Malling B et al.
Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration.
Anaesthesia.
1988;
43
533-537
EK I b
-
71
Raucoules-Aime M, Roussel L J, Rossi D et al.
Effect of severity of surgery on metabolic control and insulin requirements in insulin-dependent diabetic patients.
Br J Anaesth.
1995;
74
231-233
EK III
-
72
Furnary A P, Zerr K J, Grunkemeier G L et al.
Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.
Ann Thorac Surg.
1999;
67
352-360
EK II a
-
73
Dewey C M, Riley W J.
Have diabetes, will travel.
Postgrad Med.
1999;
105
111-118
124
EK IV
-
74 Pfohl M, Schmülling R M. Diabetes, Sport und Reisen.. In: Schatz H, Hrsg. Diabetologie kompakt.. Blackwell; 2001. EK IV
-
75
Sane T, Koivisto V A, Nikkanen P et al.
Adjustment of insulin doses of diabetic patients during long distance flights.
BMJ.
1990;
301
421-422
EK III
-
76
Driessen S O, Cobelens F G, Ligthelm R J.
Travel-related morbidity in travelers with insulin-dependent diabetes mellitus.
J Travel Med.
1999;
6
12-15
EK III
-
77
Schmülling R M, Pfohl M, Renn W et al.
Flugreisen trotz Diabetes? Der Einfluß einer westlichen und östlichen Zeitverschiebung auf den Rhythmus zirkadianer Hormone und die Stoffwechseleinstellung von Typ I-Diabetikern.
Z Allg Med.
1995;
71
212-225
EK II a
-
78
Gandhi G Y, Murad M H, Flynn D N et al.
Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials.
Clin Endocrinol (Oxf).
2008;
69
244-252
EK I a
-
79
Huurman V A, Decochez K, Mathieu C et al.
Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients.
Diabetes Metab Res Rev.
2007;
23
269-275
EK I b
-
80
Pescovitz M D, Greenbaum C J, Krause-Steinrauf H et al.
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
N Engl J Med.
2009;
361
2143-2152
EK I b
-
81
Raz I, Avron A, Tamir M et al.
Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Diabetes Metab Res Rev.
2007;
23
292-298
EK I b
-
82
Schloot N C, Meierhoff G, Lengyel C et al.
Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Diabetes Metab Res Rev.
2007;
23
276-285
EK I b
-
83
Walter M, Philotheou A, Bonnici F et al.
No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Diabetes Care.
2009;
32
2036-2040
EK I b
-
84 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) .Nationale VersorgungsLeitlinie Typ-2-Diabetes – Nierenerkrankungen bei Diabetes im Erwachsenenalter. Version Konsultation 1.0. http://http://www.diabetes.versorgungsleitlinie.de 2010 EK IV
-
85
Robertson R P.
Seminars in medicine of the Beth Israel Hospital, Boston: Pancreatic and islet transplantation for diabetes – cures or curiosities?.
N Engl J Med.
1992;
327
1861-1868
EK III
-
86
Landgraf R.
Impact of pancreas transplantation on diabetic secondary complications and quality of life.
Diabetologia.
1996;
39
1415-1424
EK III
-
87
Robertson R P, Holohan T V, Genuth S.
Therapeutic controversy: Pancreas transplantation for type I diabetes.
J Clin Endocrinol Metab.
1998;
83
1868-1874
EK III
-
88 Canadian Diabetes Association .Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. http://http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf 2008 EK IV
-
89 Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme .Qualitätssicherungsbericht 2008. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1 / Typ 2, Koronare Herzkrankheit, Asthma / COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2009 EK III
-
90
Kitabchi A E, Umpierrez G E, Miles J M et al.
Hyperglycemic crises in adult patients with diabetes.
Diabetes Care.
2009;
32
1335-1343
EK IV
-
91
Bull S V, Douglas I S, Foster M et al.
Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial.
Crit Care Med.
2007;
35
41-46
EK II b
-
92
Kitabchi A E, Umpierrez G E, Murphy M B et al.
Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association.
Diabetes Care.
2006;
29
2739-2748
EK IV
-
93 Haak T, Kellerer M (eds). Deutsche Diabetes-Gesellschaft (DDG): Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Mainz: Kirchheim; 2009 EK IV
-
94
DCCT Research Group .
Epidemiology of severe hypoglycemia in the diabetes control and complications trial.
Am J Med.
1991;
90
450-459
EK I b
-
95
Beck R W, Buckingham B, Miller K et al.
Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.
Diabetes Care.
2009;
32
1947-1953
EK I b
-
96
O’Connell M A, Donath S, O’Neal D N et al.
Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial.
Diabetologia.
2009;
52
1250-1257
EK I b
-
97
Bode B, Beck R W, Xing D et al.
Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.
Diabetes Care.
2009;
32
2047-2049
EK III
-
98
Bergenstal R M, Tamborlane W V, Ahmann A et al.
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes.
N Engl J Med.
2010;
363
311-320
EK I b
-
99
Tamborlane W V, Beck R W, Bode B W et al.
Continuous glucose monitoring and intensive treatment of type 1 diabetes.
N Engl J Med.
2008;
359
1464-1476
EK I b
-
100 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV) .Nationale VersorgungsLeitlinie Typ-2-Diabetes-Prävention und Therapie von Netzhautkomplikationen. http://http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_netzhaut/index_html 2006 EK IV
-
101 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) .Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. http://http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_neuro 2010 EK IV
-
102 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) .Nationale VersorgungsLeitlinie Typ-2-Diabetes – Präventions- und Behandlungsstrategien für Fußkomplikationen. Version 2.8. http://http://www.diabetes.versorgungsleitlinie.de 2006 EK IV
-
103 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV) .Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. http://http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro 2010
1 Herausgeber: S. Matthaei, M. Kellerer
2 Diese Klassifikation geht auf Empfehlungen der Amerikanischen Diabetes-Gesellschaft (ADA) zurück [11] und wurde sowohl von der WHO als auch von der Deutschen Diabetes-Gesellschaft (DDG) übernommen [10]
[12]
.
3 Für das Vorliegen einer diabetischen Ketoazidose werden international unterschiedliche BlutglukoseÂgrenzwerte definiert. Der Grenzwert von 250 mg / dl basiert auf dem Konsens der Autorengruppe. Da die klinischen Auswirkungen von hohen Blutglukosewerten stark variieren können, sollten die Blutglukosewerte auf der Grundlage des klinischen Bildes beurteilt werden. Eine einmalige Blutzuckermessung von mehr als 250 mg / dl ohne entsprechende Begleitparameter ist noch keine Ketoazidose.
Prof. Dr. M. Dreyer
Asklepios Westklinikum Hamburg
Suurheid 20
22559 Hamburg
Telefon: 0 40 / 81 91 27 40
eMail: manfred.dreyer@asklepios.com
